Article in Seminars in arthritis and rheumatism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
3 authors.
Rebecca B BlankDepartment of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, USA. Electronic address: rebecca.blank@nyulangone.org.
Renuka R NayakRheumatology Division, Department of Medicine, University of California, San Francisco, CA, USA.
Jose U ScherDepartment of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, USA; NYU Colton Center for Autoimmunity, New York University School of Medicine, New York, NY, USA.
Funding
Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
ELLIPSS: ELucidating the Landscape of Immunoendotypes in Psoriatic Skin and SynoviumUC2AR081029 · NIAMS · UNIVERSITY OF ROCHESTER · PI Johann Eli Gudjonsson, Wilson Liao · 2022 to 2026
$7.9M
Skeletal Biology and Biomechanics (SBB) CoreP30AR075055 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EDWARD C HSIAO · 2019 to 2026
$7.1M
Lupus Omics Cutaneous Kidney Investigative Team (LOCKIT) - Pain SupplementUC2AR081039 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jill P Buyon, MICHELLE A PETRI · 2022 to 2026
$6.3M
Employing the gut microbiome to accelerate effective initiation of rheumatoid arthritis therapyR01AR074500 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Renuka Rajendra Nayak, Jose U. Scher · 2019 to 2026
$4.1M
From here to eternity: gut microbial response to drug therapy and inflammationR35GM151349 · NIGMS · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Renuka Rajendra Nayak · 2023 to 2026
$1.5M
The impact of the gut microbiome on rheumatoid arthritis treatmentK08AR073930 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAYAK, RENUKA RAJENDRA · 2018 to 2022
$981k
Microbial metabolites impacting the response to methotrexate in rheumatoid arthritisR03AR082036 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAYAK, RENUKA RAJENDRA · 2023 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Can we modulate the gut microbiome to enhance DMARD efficacy in rheumatoid arthritis? · full record | OpenQuestion